Finished product reference
Edrophonium Chloride
Injection · Parenteral · 10 mg/1mL · 1 mL
- List code
- 12322
- Pharmacologic class
- Short-acting cholinesterase inhibitor (parasympathomimetic)
What it is and how it works
Edrophonium is a quaternary ammonium compound that reversibly inhibits acetylcholinesterase, increasing acetylcholine at the neuromuscular junction and at muscarinic sites. Its action is rapid in onset (within about 1 minute) and brief (about 5–10 minutes).
Indications
Diagnosis of myasthenia gravis (Tensilon test) and differentiation of myasthenic from cholinergic crisis; reversal of non-depolarising neuromuscular blockade in some settings.
Dosage and administration (summary)
Diagnostic test in adults: typically 2 mg intravenously, followed after 30–45 seconds by a further 8 mg if there is no adverse reaction; an anticholinergic (atropine) should be immediately available.
Contraindications
Mechanical intestinal or urinary obstruction and hypersensitivity to edrophonium.
Warnings and precautions
Can cause severe bradycardia, cardiac arrest, bronchospasm and increased secretions; use with great caution in asthma, cardiac arrhythmias, recent myocardial infarction, hypotension and epilepsy. Resuscitation equipment and atropine must be available during testing. Because of its brief action it is not used for maintenance therapy.
Pregnancy
Use only if clearly needed; data are limited.
Storage and supply
Store below 25 °C, protected from light.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.